株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオバンキング市場の予測:医療研究・治療用の見通し、主要企業、主要地域

Biobanking Market Forecasts 2017-2027: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells, Leading Biobanking Companies and Key Geographies

発行 Visiongain Ltd 商品コード 229862
出版日 ページ情報 英文 259 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=153.38円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオバンキング市場の予測:医療研究・治療用の見通し、主要企業、主要地域 Biobanking Market Forecasts 2017-2027: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells, Leading Biobanking Companies and Key Geographies
出版日: 2017年08月16日 ページ情報: 英文 259 Pages
概要

世界のバイオバンキングの総合収益は、2027年に530億米ドルを上回ると予測されています。

当レポートでは、世界のバイオバンキング市場について調査分析し、収益予測に焦点を当てて、データ、動向、機会、ビジネス見通しについて検証して、体系的な情報を提供しています。

第1章 レポート概要

第2章 イントロダクション:バイオバンキングとその応用

  • ヒト組織バンキング市場の定義
  • 幹細胞バンキング市場の定義
  • バイオバンキングとは
  • バイオバンクの主な特性
  • バイオバンキングに含まれるプロセスとは
  • バイオバンクの分類
  • バイオバンキングの指針と基準
  • バイオバンクベース研究に対する法規制
  • バイオバンキングと製薬業

第3章 医療用バイオバンキング:世界市場

  • 世界の医療用バイオバンキング市場
  • 医療用バイオバンキング:研究 vs. 治療用
  • 世界の医療用バイオバンキング市場:収益予測
  • バイオバンクの保管
  • 世界の医療用バイオバンキング市場:部門別
  • 研究用バイオバンキング:ほとんどが非営利
  • 将来の治療用バイオバンキング

第4章 研究用バイオバンキング

  • 研究用バイオバンキングの内訳:組織タイプ別
  • 研究用バイオバンキング:比較 (組織タイプ別)
  • 研究用バイオバンキング (組織タイプ別) :収益予測
  • 研究用バイオバンキングの試料の数
  • 研究用ヒト組織バンキング市場
  • 研究用ヒト組織バンキング市場:収益予測
  • ヒト組織バンキング市場:商業 vs. 公共部門別
  • 研究用幹細胞バンキング市場
  • 研究用幹細胞バンキング市場:収益予測
  • その他の研究用バンキング市場
  • その他の研究用バンキング市場:収益予測

第5章 将来の治療用幹細胞バンキング

  • 治療用幹細胞バンキング:幹細胞タイプ別
  • 治療用幹細胞バンキング (幹細胞タイプ別) :収益の比較と市場シェア
  • 治療用幹細胞バンキング (幹細胞タイプ別) :収益予測
  • 貯蔵される幹細胞の規模
  • 臍帯血バンキング市場
  • 臍帯血バンキング市場:収益予測
  • 成体幹細胞バンキング市場
  • 成体幹細胞バンキング市場:収益予測

第6章 主要国市場の予測

  • バイオバンキングの地域別フットプリント
  • 医療用バイオバンキング:米国が先導
  • 主要国市場:収益予測
  • 地域別の市場シェアの変動
  • 米国
  • 欧州主要国
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
    • オランダ
  • 日本
  • BRIC諸国
    • 中国
    • インド
    • ブラジル
    • ロシア

第7章 バイオバンキング技術:システム、ソフトウェア、消耗品、サービス

  • バイオバンキング関連市場:概要
  • システム技術:完全自動処理
  • 貯蔵技術:持続可能性、サンプルトラッキングの容易性、追加のセキュリティ
  • バイオバンク用ソフトウェア
  • 消耗品:効果的なサンプル管理に求められる高品質性
  • バイオバンキングサービス:生物試料の貯蔵、管理、輸送

第8章 バイオバンキング市場の主要企業

  • バイオバンキング企業のビジネスモデル:調達 vs. 保管
  • 研究用の商業バイオバンク
    • Tissue Solutions
    • Asterand Bioscience
    • Biopta
    • BioServe
    • Coriell Institute for Medical Research
  • 治療用の有力バイオバンク
    • Cord Blood America
    • Cryo-Cell International
    • Cryo-Save
    • China Cord Blood Corp
    • LifebankUSA
    • ViaCord
    • Cord Blood Registry
    • Biogenea Pharmaceuticals
    • StemLife
    • Future Health Biobank
    • Caladrius Biosciences
    • Precious Cells

第9章 バイオバンキング市場の定性分析

  • 産業動向
  • 市場の強みと弱み
  • 市場の機会と脅威
  • STEP分析

第10章 結論

第11章 用語集

目次
Product Code: PHA0225

Biobanking - our new study reveals trends, R&D progress, and predicted revenues

Where is the Biobanking market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 259-page report provides 144 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Biobanking. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biobanking market. See how to exploit these opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and following Biobanking Submarkets:

  • Biobanking for Research
    • Human Tissue
    • Commercial
    • Public
    • Stem Cells
    • Others (DNA, Blood fluids etc.)
  • Biobanking for Therapeutic Use
    • Umbilical Cord Banking
    • Adult Stem Cell Banking

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets:

  • The US
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • The Netherlands
  • Japan
  • China
  • India
  • Brazil
  • Russia
  • RoW

Our analysis shows activities of biobanks, including these organisations:

  • Stemgent
  • Biopta
  • BioServe
  • Coriell Institute for Medical Research
  • Cord Blood America
  • Cryo-Cell International.

And other companies, including these:

  • China Cord Blood Corp
  • LifebankUSA
  • ViaCord
  • Cord Blood Registry
  • Biogenea Pharmaceuticals
  • StemLife
  • Caladrius Biosciences.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and the US in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth

Overall world revenue for Biobanking will surpass $53bn in 2027, our work calculates. This will be driven by the use of biobanking in drug development and medical research, as well as the expected rise in number of commercial biobanks over the forecast period

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biobanking Market report helps you

In summary, our 259-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Biobanking market and Leading Submarkets - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 12 of the leading national markets - US, Germany, France, UK, Italy, Spain, Netherlands, Japan, Russia, China, India, Brazil
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles for 17 companies involved in commercial biobanking and biobanking for therapeutic use

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biobanking market and leading companies. You will find data, trends and predictions.

Get our report today Biobanking Market Forecasts 2017-2027: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells, Leading Biobanking Companies and Key Geographies. Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Biobanking for Medicine: World Market Review 2017 and Global Segmentation
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Biobanking and its Applications

  • 2.1 Defining the Human Tissue Banking Market for the Scope of this Report
  • 2.2 The Stem Cell Banking Market - Our Breakdown
  • 2.3 What is Biobanking?
  • 2.4 Main Features of Biobanks
  • 2.5 What Processes are Involved in Biobanking?
  • 2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
    • 2.6.1 Volunteer Group: General vs. Disease Population
    • 2.6.2 Ownership Structure: Public vs. Private
  • 2.7 The Guidelines and Standards for Biobanking
  • 2.8 Laws and Regulations for Biobank-Based Research
    • 2.8.1 HIPAA Amendments
  • 2.9 Biobanking and the Pharmaceutical Industry
    • 2.9.1 Biobanking in Research, Drug Discovery and Development
      • 2.9.1.1 Biobanking - Facilitates Genetic Epidemiology Studies
      • 2.9.1.2 Novel Drug Discovery through Better Understanding of Disease Pathways
      • 2.9.1.3 Biomarker Discovery in Drug Development
    • 2.9.2 Biobanking for Therapeutic Purposes
    • 2.9.3 Biobanking in Clinical Trials

3. Biobanking for Medicine: World Market 2017 to 2027

  • 3.1 The World Biobanking for Medicine Market in 2017
  • 3.2 Biobanking for Medicine: Research vs. Therapeutics in 2022 and 2027
  • 3.3 World Biobanking for Medicine Market: Overarching Revenue Forecast 2017 to 2027
  • 3.4 Biobanks Stored More Than 1.5 Billion Specimens in 2017
  • 3.5 The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2017 to 2027
  • 3.6 Biobanking for Research: Mostly Non-Profit
    • 3.6.1 Biobanking for Research: Revenue Forecast 2017 to 2027
    • 3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
  • 3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
    • 3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
    • 3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2017 to 2027
    • 3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2017 to 2027

4. Biobanking for Research Purposes

  • 4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2017
  • 4.2 Biobanking for Research in 2022 and 2027: Comparison by Tissue Type
  • 4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2017 to 2027
  • 4.4 How Many Specimens are Biobanked for Research?
  • 4.5 The Human Tissue Banking Market for Research in 2017
  • 4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2017 to 2027
  • 4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
    • 4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2017 to 2027
    • 4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2017 to 2027
  • 4.8 The Stem Cell Banking Market for Research in 2017
  • 4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2017 to 2027
    • 4.9.1 R&D- Growing Interest Towards iPSCs
  • 4.10 Banking of Other Biologics Specimens for Research in 2017
  • 4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2017 to 2027

5. Stem Cell Banking for Future Therapeutic Use

  • 5.1 Stem Cell Banking for Therapeutic Use in 2017: A Breakdown by Stem Cell Type
  • 5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2022 and 2027
  • 5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
  • 5.4 How Many Stem Cells Are Biobanked Each Year?
  • 5.5 The Umbilical Cord Blood Banking Market in 2017
    • 5.5.1 Private vs. Public Cord Blood Banking
    • 5.5.2 Umbilical Cord Blood Banking: The Controversies
  • 5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2017 to 2027
  • 5.7 The Adult Stem Cell Banking Market in 2017
  • 5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2017 to 2027

6. Leading National Markets 2017 to 2027

  • 6.1 The Geographical Footprint of Biobanking
    • 6.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
    • 6.1.2 Biobanks in the US: A Fragmented Picture
    • 6.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
  • 6.2 Biobanking for Medicine: The US Led the Way in 2017
  • 6.3 The Leading National Markets: Grouped Revenue Forecasts 2017 to 2027
  • 6.4 How Will Regional Market Shares Change to 2027?
  • 6.5 The US Biobanking Market 2017 to 2027: Diversifying and Expanding
  • 6.6 The Top European Biobanking Markets 2017 to 2027: Leading the Way in Biobanking Infrastructure
    • 6.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
    • 6.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
    • 6.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
    • 6.6.4 UK: Limited Presence of Biobanking Networks
    • 6.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
    • 6.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
  • 6.7 The Japanese Biobanking Market 2017 to 2027: A High Level of Government Investment Drives Growth
  • 6.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2017 and 2027
    • 6.8.1 The Chinese Biobanking Market 2017 to 2027: The High Rate of Growth Will Continue
    • 6.8.2 The Indian Biobanking Market 2017 to 2027: Set to Become the Leading Market for Private Stem Cell Banking?
    • 6.8.3 The Brazilian Biobanking Market 2017 to 2027: Will New Regulations Drive or Restrain the Market?
    • 6.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2017 to 2027?

7. Technology for Biobanking: Systems, Software, Consumables, and Services Associated with Biobanking

  • 7.1 The Biobanking-Associated Market: Overview
  • 7.2 Systems Technology: Fully Automated Handling
    • 7.2.1 Automated Liquid Handling Systems
    • 7.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
    • 7.2.3 Automated DNA Isolation
  • 7.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
    • 7.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
    • 7.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
    • 7.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
    • 7.3.4 Automated Storage and Retrieval Systems: Essential Technology
    • 7.3.5 RFID and Tagging Technology: Advantages over Barcodes
  • 7.4 Software for Biobanks
    • 7.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
    • 7.4.2 LIMS Functions
  • 7.5 Consumables: High Quality Required for Effective Sample Management
    • 7.5.1 Addressing Sample Storage and Tracking Issues
  • 7.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

8. Leading Companies in the Biobanking Market

  • 8.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
  • 8.2 Commercial Biobanks for Research Purposes in 2017
    • 8.2.1 Tissue Solutions: A Virtual Biobank with a Global Presence
      • 8.2.1.1 An Overview of the Products and Services Offered by Tissue Solutions
      • 8.2.1.2 Banked Samples Occur in Many Formats
      • 8.2.1.3 Prospective Tissue Collection for Hard-to-Find Samples
      • 8.2.1.4 Fresh Samples from Surgical Resections are in High Demand
      • 8.2.1.5 Freshly Isolated Human Cells are a Valuable Research Tool
      • 8.2.1.6 FDA/EMA Panel of Normal Tissues
      • 8.2.1.7 Strengths, Capabilities and the Future Outlook for Tissue Solutions
    • 8.2.2 Asterand Bioscience is now Part of Stemgent
      • 8.2.2.1 Asterand's Products and Services: XpressBANK, BioSpoke and PhaseZERO
      • 8.2.2.2 The Future Outlook for Asterand
    • 8.2.3 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
      • 8.2.3.1 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
      • 8.2.3.2 The First Catalogue of Assays Based on Human Functional Tissues
      • 8.2.3.3 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
    • 8.2.4 BioServe: One of the World's Largest Commercial Biorepositories
      • 8.2.4.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
      • 8.2.4.2 The Future Outlook for BioServe
    • 8.2.5 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
      • 8.2.5.1 Features of and Recent Developments at Coriell Biobank
      • 8.2.5.2 Future Outlook for the Coriell Biobank
  • 8.3 Prominent Biobanks for Therapeutic Use in 2017
    • 8.3.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
    • 8.3.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
    • 8.3.3 Cryo-Save's Educational Programme Benefits Company's Growth
    • 8.3.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
    • 8.3.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
    • 8.3.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
    • 8.3.7 Cord Blood Registry: The World's Largest Newborn Stem Cell Company Will Be Promoted By New Parent Company
    • 8.3.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
    • 8.3.9 StemLife is Reportedly Facing Challenges due to Government Regulations in Malaysia
    • 8.3.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
    • 8.3.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
    • 8.3.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

9. Qualitative Analysis of the Biobanking Market 2017 to 2027

  • 9.1 Industry Trends
    • 9.1.1 The Growing Demand for Biobank Resources for Research
    • 9.1.2 The Establishment of Biobanking Networks
  • 9.1.2.1 BBMRI: The Most Extensive Biobank Network
    • 9.1.3 Virtual Biobanks: Connecting a Fragmented Industry
    • 9.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
    • 9.1.5 Automated Biobanking Has Become Imperative
    • 9.1.6 Increasing Uptake of LIMS
    • 9.1.7 Green Banking - Becoming More Energy Efficient
  • 9.2 The Strengths and Weaknesses of the Biobanking Market in 2017
    • 9.2.1 HBS are Valuable Resources for R&D
    • 9.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
    • 9.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
    • 9.2.4 The Effect of Big Data on Biobanking
    • 9.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
    • 9.2.6 Biobanks are Fragmented and Uncoordinated
    • 9.2.7 Lack of Standardisation is a Weakness of the Industry
    • 9.2.8 Lack of Public Awareness Limits Number of Donors
    • 9.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
  • 9.3 Opportunities and Threats Facing the Biobanking Market, 2017 to 2027
    • 9.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
    • 9.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
    • 9.3.3 Biobanking Networks as a Basis for Personalised Medicine
    • 9.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
    • 9.3.5 Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
    • 9.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
    • 9.3.7 Limitations Surrounding Informed Consent
  • 9.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2017 to 2027

10. Conclusions from Our Research and Analysis

  • 10.1 World Biobanking Market 2017 to 2027: High Revenue Growth Predicted
  • 10.2 Biobanking for Research 2017 to 2027: The Value of Biobanked Specimens is Increasingly Recognised
  • 10.3 Biobanking for Therapeutic Use 2017 to 2027: Rapid Expansion in Adult Stem Cell Banking
  • 10.4 The Leading National Markets: High Sales Growth Worldwide
  • 10.5 Current and Future Trends in Biobanking
    • 10.5.1 Increasing Demand for Biobanked Samples - Increasing Revenue
    • 10.5.2 Improving Biobanking Infrastructure - Growth Driver and a Need for Strategic Planning for Sustainability
    • 10.5.3 Marked Challenges, but Opportunities for Expansion

11. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1 Global Biobanking Industry Segmentation Overview, 2017
  • Figure 2.1 Processes Involved in Biobanking, 2017
  • Figure 2.2 The Classification of Biobanks, 2017
  • Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2017
  • Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2022
  • Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2027
  • Figure 3.4 Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2017 to 2027
  • Figure 3.5 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. Of Samples (m), 2017 to 2027
  • Figure 3.6 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), 2017 to 2027
  • Figure 3.7 Biobanking Market for Research: Revenue Forecast ($bn), 2017 to 2027
  • Figure 3.8 Biobanking for Research: Drivers and Restraints, 2017 to 2027
  • Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2017 to 2027
  • Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2016 to 2027
  • Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Share (%), 2017
  • Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2022
  • Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2027
  • Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2017 to 2027
  • Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2017 to 2027
  • Figure 4.6 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2017 to 2027
  • Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($bn), 2017 to 2027
  • Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2017 to 2027
  • Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2017
  • Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2022
  • Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Share (%), 2027
  • Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2017 to 2027
  • Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($bn), 2017 to 2027
  • Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2017 to 2027
  • Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2017 to 2027
  • Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2017 to 2027
  • Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2017 to 2027
  • Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2016 to 2027
  • Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2017
  • Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2022
  • Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2027
  • Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2017 to 2027
  • Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2017 to 2027
  • Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2017 to 2027
  • Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2017 to 2027
  • Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2017 to 2027
  • Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2017 to 2027
  • Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2017 to 2027
  • Figure 6.1 The Leading National Biobanking Markets: Market Shares (%), 2017
  • Figure 6.2 The Leading National Markets: Grouped Revenue Forecasts ($bn), 2017 to 2027
  • Figure 6.3 The Leading National Markets: Market Share (%), 2022
  • Figure 6.4 The Leading National Markets: Market Share (%), 2027
  • Figure 6.5 Biobanking for Medicine in the US: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.6 Driving and Restraining Factors of the US Biobanking Market, 2017 to 2027
  • Figure 6.7 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2017 to 2027
  • Figure 6.8 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2017 to 2027
  • Figure 6.9 The German Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.10 The French Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.11 The Italian Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.12 The UK Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.13 The Spanish Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.14 The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.15 The Japanese Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.16 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2017 to 2027
  • Figure 6.17 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2017 to 2027
  • Figure 6.18 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2017 to 2027
  • Figure 6.19 The Chinese Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.20 The Indian Biobanking Industry: Revenue ($bn) Forecast, 2017 to 2027
  • Figure 6.21 The Brazilian Biobanking Market: Revenue Forecast ($bn), 2017 to 2027
  • Figure 6.22 The Russian Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
  • Figure 7.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2017
  • Figure 7.2 The Basic Function of LIMS
  • Figure 8.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2017
  • Figure 8.2 Business Model: Commercial Banking of Biological Samples, 2017
  • Figure 8.3 China Cord Blood Corp: Revenue ($m), 2014 to 2016
  • Figure 8.4 StemLife: Comparison of Revenue ($m), 2015 and 2016
  • Figure 10.1 The Global Biobanking Market by Industry Sector: Comparison of Revenues ($bn), 2017, 2022 and 2027
  • Figure 10.2 Biobanking for Research by Sample Type: Comparison of Revenues ($bn), 2017, 2022 and 2027
  • Figure 10.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn), 2017, 2022 and 2027
  • Figure 10.4 Leading Regional Markets for Biobanking: Comparison of Revenues ($bn), 2017, 2027 and 2027

List of Tables

  • Table 1.1 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027 (redacted)
  • Table 2.1 Prominent Population-Based Biobanks, 2017
  • Table 2.2 Prominent Disease-Based Biobanks, 2017
  • Table 2.3 Guidelines and Recommendations for Biobanks, 2017
  • Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2017
  • Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2017
  • Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2017
  • Table 3.2 Biobanking for Medicine: Research vs. Therapeutics in 2022 and 2027
  • Table 3.3 Biobanking for Medicine: Overall World Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 3.4 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast No. Of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 3.5 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 3.6 Biobanking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 3.7 Biobanking for Therapeutic Use Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2016 to 2027
  • Table 4.1 The Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2017
  • Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2022 and 2027
  • Table 4.3 Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.4 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.5 The Human Tissue Banking Market Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Share (%), 2017, 2022 and 2027
  • Table 4.7 Commercial Human Tissue Banking Forecast, Revenue ($bn) Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.8 Commercial Human Tissue Banking Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.9 Prominent Commercial Human Tissue Banks, 2017
  • Table 4.10 Public Sector Human Tissue Banking Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.11 Prominent Public-Funded Human Tissue Banks, 2016
  • Table 4.12 The Stem Cell Banking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2017
  • Table 4.14 Banking of Other Biologic Specimens for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2017
  • Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Share (%), 2017
  • Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Share (%), 2022 and 2027
  • Table 5.3 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 5.5 Prominent Public and Private Cord Blood Banks, 2017
  • Table 5.6 The Umbilical Cord Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2017
  • Table 5.8 The Adult Stem Cell Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.1 Breakdown of BBMRI Network Directory Members by Country, 2017
  • Table 6.2 The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2017
  • Table 6.3 Leading National Markets Grouped Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.4 Leading National Markets: Comparison of Market Share (%), 2017, 2022 and 2027
  • Table 6.5 Biobanking for Medicine in the US Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.6 The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.7 Examples of Biobanking Initiatives Funded by the European Commission, 2016
  • Table 6.8 The German Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.9 The French Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.10 The Italian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.11 The United Kingdom Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.12 The Spanish Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.13 Prominent Clinical and Population Biobanks in the Netherlands, 2017
  • Table 6.14 The Netherlands Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.15 The Japanese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.17 The Chinese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.18 The Indian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.19 Prominent Research Biobanks in India, 2017
  • Table 6.20 The Brazilian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 6.21 The Russian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
  • Table 7.1 Prominent Companies Providing Automated Liquid Handling Technology, 2017
  • Table 7.2 Prominent Companies Providing Room Temperature Storage Solutions, 2017
  • Table 7.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80∞C), 2017
  • Table 7.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2017
  • Table 7.5 Prominent Companies Providing Cryogenic Storage Solutions, 2017
  • Table 7.6 Prominent Providers of Automated Biobanking Systems, 2017
  • Table 7.7 Major Vendors in the LIMS Market, 2017
  • Table 7.8 Prominent Vendors of Consumables for Biobanking, 2017
  • Table 7.9 Prominent Biorepository Service Providers, 2017
  • Table 8.1 Prominent Players in the Biobanking Industry for Research, 2017
  • Table 8.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2017
  • Table 8.3 China Cord Blood Corp: Revenue ($m), Total Units Stored for Subscribers, and No. Of New Subscribers, 2014 to 2016
  • Table 8.4 StemLife: Comparison of Revenue ($m) between 2015 and 2016
  • Table 9.1 Strengths and Weaknesses of the Biobanking Industry, 2017
  • Table 9.2 Opportunities and Threats Facing the Biobanking Industry, 2016 to 2027
  • Table 9.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2016 to 2027

Companies Listed

  • Abbott Laboratories
  • AIS
  • AKH Biobank
  • AllCells
  • American CryoStem
  • American Type Culture Collection
  • Analytical Biological Services
  • ARUP Laboratories
  • ASPREE Healthy Ageing Biobank
  • Assure Immune
  • Asterand
  • AstraZeneca
  • Aurora Biomed
  • Auto scribe Informatics
  • Bangalore Brain Bank
  • Barts Gynae Tissue Bank
  • Bayer
  • BBMRI
  • Beckman Coulter
  • BINDER
  • Bio Fortis
  • Bio Life Solutions
  • Bio Repository Resources
  • BioCision
  • Biogenea
  • Biomatrica
  • Biopta
  • BioreclamationIVT
  • BioRep
  • BioServe Biotechnologies
  • BioSHARE
  • Biovault Technical
  • BIOVIA
  • BrainNet Europe
  • Bristol-Myers Squibb
  • Brooks Automation (acquired Bio Storage Technologies)
  • Brooks Life Science Systems
  • Caladrius Biosciences
  • Cambridge Biomedical Research Centre
  • CARTaGENE
  • CCLG Tissue Bank
  • Cells4Life
  • Celltex Therapeutics
  • Cesca Therapeutics
  • China Cord Blood Corp
  • China Kadoorie Biobank
  • CLB/Amsterdam Medical Center
  • CMD Biobank
  • CONCOR
  • CorCell
  • Cord Blood America
  • Cord Life
  • CORE Informatics
  • Coriell Institute for Medical Research
  • Cryo Bio System
  • Cryo-Cell
  • Cryo-Cell International
  • Cryogene Lab
  • CryoLogic
  • Cryo-Save
  • Cureline
  • Custom Biogenic Systems
  • Cybrdi
  • Cybrdi
  • DeCODE Genetics (Amgen)
  • Eli Lilly
  • ENGAGE
  • Eppendorf
  • Esco
  • ESFRI
  • Fisher Bio Services
  • FluidX
  • Future Health Biobank
  • GE Healthcare SeqWright Genomic Services
  • GEN2PHEN
  • Genentech
  • Gilson
  • GlaxoSmithKline
  • Haier Biomedical
  • Hamilton Robotics
  • Hamilton Storage Technologies
  • Hospital Necker Paris
  • Hudson Robotics
  • Hungarian Biobank
  • Huntington Disease Biobank
  • In biomed
  • Indivumed
  • Infectious Disease Biobank
  • IntegenX
  • International Stem Cell Corporation
  • Kaiser Permanente
  • King's College London Tissue Bank
  • Lab ware
  • LABVANTAGE
  • Leiden Longevity
  • Leiden University Medical Center
  • Life Bank USA
  • Life Gene
  • Life Lines Biobank
  • Malm? Microbiology Biobank
  • Merck
  • Micronics
  • Mitochondrial Disease Biobank
  • NESDA
  • Novare Biologistics
  • Novartis
  • Ocimum Bio solutions
  • OnCore UK
  • Organisation for Economic Co-operation and Development (OECD)
  • OriGene
  • Pacific Bio Storage
  • PALGA
  • Panasonic Biomedical
  • Parelsnoer
  • PerkinElmer
  • Pfizer
  • Pharma Cells
  • PHOEBE
  • Pop-Gen National Cohort
  • Precious Cells
  • Precision Bio services
  • PrecisionMed
  • PREVEND
  • Progenicyte
  • ProMedDx
  • ProteoGenex
  • Qiagen
  • Riken BRC Cell Bank
  • Roche
  • Sapien Biosciences
  • ScÈil
  • Smart Cells
  • StarLIMS
  • Steelgate
  • Stem Life
  • Stem Save
  • Stemcyte
  • System Biosciences
  • Taiyo Nippon Sanso
  • TAP Bio systems (now owned by Sartorius Stedim Biotech)
  • TCG Life Sciences Tissue Bank
  • Tecan
  • Thermo Fisher Scientific
  • TISS-EU Project
  • Tissue Solutions
  • TTP Labtech
  • UCL Biobank
  • US Biomax
  • Via Cord
  • Virgin Health Bank

List of Organisations:

  • Chernobyl Tissue Bank
  • Cord Blood Registry (CBR)
  • Estonian Genome Project
  • FDA
  • Germany's Institut für Qualit&&frac‰t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • Harvard Stem Cell Institute
  • Imperial Tissue Bank
  • Japanese Ministry of Health, Labour and Welfare
  • Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
  • Netherlands Twin Registry
  • NHS
  • NHS Blood and Transplant Cord Blood Bank
  • NICE
  • Singapore Cord Blood Bank
  • Stanford Tissue Bank
  • Swedish Institute for Infectious Disease Control Biobank
  • Tata Memorial Hospital Tissue Bank
  • The Cambridge Brain Bank
  • The Guangzhou Biobank
  • The National Cancer Tissue Bank, Indian Institute of Technology
  • UK Biobank
  • UK ME-CFS Biobank
  • UK Multiple Sclerosis Tissue Bank
  • UK Parkinson's Disease Tissue Bank
  • UK Stem Cell Bank
  • University of Toebingen
  • WHO
  • Wisconsin International Stem Cell Bank
Back to Top